GRP-056 Effect of Pharmaceutical Follow-Up in Patients with Secondary Hyperparathyroidism Treated with Cinacalcet
نویسندگان
چکیده
منابع مشابه
Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients
BACKGROUND Secondary hyperparathyroidism (SHPT) is one of the major risk factors of morbidity and mortality in end-stage renal disease. Cinacalcet effectively controls SHPT without causing hypercalcemia and hyperphosphatemia. However, there is significant inter-individual response variance to cinacalcet treatment. Therefore, we aimed to evaluate the genetic effects related with parathyroid horm...
متن کاملSuccessful treatment of inoperable recurrent secondary hyperparathyroidism with cinacalcet HCl
Secondary hyperparathyroidism is a common complication for patients with end-stage renal disease (ESRD). When it progresses, it is associated with morbidity and mortality [1]. Phosphate binders and vitamin D can be used to prevent the progression of secondary hyperparathyroidism. However, these conservative treatments often fail to control severe hyperparathyroidism. In such cases, parathyroide...
متن کاملTreatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism
BACKGROUND Sclerostin is a paracrine acting factor, which is expressed in the osteocytes and articular chondrocytes. Sclerostin decreases the osteoblast-related bone formation through the inhibition of the Wnt/β-catenin pathway. Osteocytes also express the Calcium sensing receptor which is a target for cinacalcet. The aim of this study was to assess the influence of six-month cinacalcet treatme...
متن کاملBone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism
The multicenter, single-arm BONAFIDE study characterized the skeletal response to cinacalcet in adult dialysis patients with plasma parathyroid hormone (PTH) levels of 300 pg/ml or more, serum calcium of 8.4 mg/dl or more, bone-specific alkaline phosphatase over 20.9 ng/ml and biopsy-proven high-turnover bone disease. Of 110 enrolled patients, 77 underwent a second bone biopsy with quantitative...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Hospital Pharmacy
سال: 2013
ISSN: 2047-9956,2047-9964
DOI: 10.1136/ejhpharm-2013-000276.056